Kooperativer Bibliotheksverbund

UID:

Format: xxvi, 545 Seiten , Illustrationen, Diagramme

ISBN: 9780323855037

Content: Intro -- Advanced Drug Delivery Systems in the Managementof Cancer -- Copyright -- Dedication -- Contents -- Contributors -- Editor biographies -- Chapter 1 Introduction to cancer cell biology -- 1 Introduction -- 2 Types of cancer -- 3 Pathophysiology of cancer -- 3.1 Sustained multiplication (proliferative) signaling -- 3.2 Shunning of anti-growth signals -- 3.3 Avoidance of immune annihilation (destruction) -- 3.4 Avoidance of apoptosis -- 3.5 Tissue invasion and metastasis -- 3.6 Extended (sustained) tumor angiogenesis -- 3.7 Endless multiplication (replication) potential

Content: 3.8 Deregulation of cell energetics -- 3.9 Oncogenes and tumor suppressor genes -- 3.10 Breast cancer biology -- 3.11 Gastric cancer biology -- 3.12 Pancreatic cancer biology -- 3.13 Lung cancer biology -- 3.14 Leukemia biology -- References -- Chapter 2 Current practice in cancer pharmacotherapy -- 1 Introduction -- 1.1 Lung -- 1.2 Breast (female) -- 1.3 Prostate -- 1.4 Colon -- 1.5 Skin -- 2 Conclusions -- References -- Chapter 3 Current practices in oncology drug delivery -- 1 Introduction -- 1.1 Historical background -- 1.2 Ancient theories about cancer

Content: 1.3 Description and epidemiology of cancer -- 2 Past therapeutic approaches in cancer (1900 and earlier) -- 3 Current approaches of drug delivery -- 3.1 Targeted therapy in cancer -- 3.1.1 Molecular targeted therapy -- 3.1.2 Monoclonal antibodies -- 3.1.3 Immunotoxins -- 3.2 Gene therapy -- 3.2.1 Gene therapy in clinics -- 3.3 Bacterial-mediated therapy -- 3.4 Nanomedicine -- 3.5 Immune checkpoint inhibitors -- 3.6 Radiomics and pathomics -- 3.6.1 Combining radiomics and pathomics with genomics -- 3.6.2 Combining radiomics and pathomics with artificial intelligence

Additional Edition: Erscheint auch als Online-Ausgabe ISBN 978-0-323-90079-9

Language: English

Subjects: Chemistry/Pharmacy

UID:

Format: 1 online resource (574 pages)

ISBN: 0-323-90079-8 , 0-323-85503-2

Note: Intro -- Advanced Drug Delivery Systems in the Managementof Cancer -- Copyright -- Dedication -- Contents -- Contributors -- Editor biographies -- Chapter 1 Introduction to cancer cell biology -- 1 Introduction -- 2 Types of cancer -- 3 Pathophysiology of cancer -- 3.1 Sustained multiplication (proliferative) signaling -- 3.2 Shunning of anti-growth signals -- 3.3 Avoidance of immune annihilation (destruction) -- 3.4 Avoidance of apoptosis -- 3.5 Tissue invasion and metastasis -- 3.6 Extended (sustained) tumor angiogenesis -- 3.7 Endless multiplication (replication) potential -- 3.8 Deregulation of cell energetics -- 3.9 Oncogenes and tumor suppressor genes -- 3.10 Breast cancer biology -- 3.11 Gastric cancer biology -- 3.12 Pancreatic cancer biology -- 3.13 Lung cancer biology -- 3.14 Leukemia biology -- References -- Chapter 2 Current practice in cancer pharmacotherapy -- 1 Introduction -- 1.1 Lung -- 1.2 Breast (female) -- 1.3 Prostate -- 1.4 Colon -- 1.5 Skin -- 2 Conclusions -- References -- Chapter 3 Current practices in oncology drug delivery -- 1 Introduction -- 1.1 Historical background -- 1.2 Ancient theories about cancer -- 1.3 Description and epidemiology of cancer -- 2 Past therapeutic approaches in cancer (1900 and earlier) -- 3 Current approaches of drug delivery -- 3.1 Targeted therapy in cancer -- 3.1.1 Molecular targeted therapy -- 3.1.2 Monoclonal antibodies -- 3.1.3 Immunotoxins -- 3.2 Gene therapy -- 3.2.1 Gene therapy in clinics -- 3.3 Bacterial-mediated therapy -- 3.4 Nanomedicine -- 3.5 Immune checkpoint inhibitors -- 3.6 Radiomics and pathomics -- 3.6.1 Combining radiomics and pathomics with genomics -- 3.6.2 Combining radiomics and pathomics with artificial intelligence -- 3.6.3 Combining radiomics and pathomics with tumor markers. , 3.6.4 Combining radiomics with pathomics immunological detection -- 3.7 Theranostics -- 4 Future directions -- References -- Chapter 4 Emerging need of advanced drug delivery systems in cancer -- 1 Introduction -- 2 Multidrug resistance in cancer cells -- 3 Toxic effects of chemotherapy -- 4 Hazardous effects of radiation oncology -- 5 Polypharmacology in anticancer therapy -- 6 Advanced drug delivery systems -- 7 Stimuli-responsive drug delivery systems -- 7.1 pH-responsive -- 7.2 Light-responsive -- 7.3 Redox-responsive -- 7.4 Enzyme-responsive -- 8 Conclusion and future perspectives -- References -- Chapter 5 Target drug delivery in cancer -- 1 Introduction -- 2 Ligand-mediated targeting (surface modification) -- 2.1 Peptide as targeting ligand -- 2.2 Aptamer-mediated drug targeting -- 2.3 Small molecule-mediated targeted drug delivery -- 2.3.1 Folate receptor targeting -- 2.3.2 Anisamide-mediated targeting -- 2.3.3 Sugar-mediated targeting -- 3 Protein-mediated targeting -- 3.1 Antibody-mediated targeting -- 3.2 Transferrin-mediated targeting -- 3.3 Lectin-mediated drug delivery -- 4 Carbohydrate-mediated drug delivery -- 4.1 Hyaluronic-mediated targeted drug delivery -- 5 Physical targeting via EPR effects -- 6 Triggered targeting -- 7 Concluding remarks -- References -- Chapter 6 Material and strategies used in oncology drug delivery -- 1 Introduction -- 2 Materials and stratagem applied in cancer therapy -- 2.1 Nanocarriers for drug delivery -- 2.1.1 Inorganic nanocarriers -- 2.1.2 Organic nanocarriers -- 2.2 Protein-based nanocarriers -- 2.3 Micelles as a drug carrier -- 2.4 Self-assembly as a drug carrier -- 2.5 Supramolecules as a delivery vehicle -- 2.6 Hydrogel as a delivery vehicle -- 2.7 Hybrid materials for controlled drug delivery -- 3 Targeted delivery: Mechanistic pathway. , 3.1 Magnetic field for cancer treatment -- 3.2 Electric field for cancer therapy -- 3.3 Thermal treatment for cancer therapy -- 4 Future challenges in cancer therapy -- 5 Conclusions -- References -- Chapter 7 Hydrogel-based drug delivery systems for cancer therapy -- 1 Introduction -- 2 Hydrogels: An overview -- 3 Hydrogel-based drug delivery systems for cancer therapy -- 3.1 Hydrogels for oral delivery -- 3.1.1 Active targeting hydrogels -- 3.2 Injectable hydrogels for local cancer therapy -- 3.2.1 Local stimuli-sensitive hydrogels -- 3.2.2 External stimuli-responsive hydrogels -- 4 Marketed/patented hydrogel-based drug delivery systems -- 5 Conclusions and future perspectives -- References -- Chapter 8 Recent advances in drug formulation development for targeting lung cancer -- 1 Introduction -- 1.1 Mechanisms of metastasis and drug resistance in lung cancer -- 2 Immunotherapy: Biomolecules targeting lung cancer -- 2.1 Antibody-based biotherapies for lung cancer -- 2.1.1 Approved biomolecules targeting epidermal growth factor receptor (EGFR) -- 2.1.2 Approved biological molecules targeting vascular endothelial growth factor (VEGF) -- 2.1.3 Approved biological molecules targeting programmed cell death ligand (PD-1) -- 2.1.4 Biomolecules under development as promising candidates for treating lung cancer -- 3 Lung cancer therapy via inhalation -- 3.1 Clinical trials of inhaled chemotherapeutics: Success or failure? -- 3.1.1 Conventional chemotherapeutic drugs for therapeutic purposes -- 3.1.2 Nonchemotherapeutic drugs as cancer chemoprevention agent -- 3.2 Current technological advances in inhalable drug delivery system (DDS) -- 3.2.1 Representative inhalable DDS based on the drug encapsulation into microparticles -- 3.2.2 Inhalable DDS based on nanotechnology approach -- 3.2.2.1 Liposome. , 3.2.2.2 Polymeric nanoparticle -- 3.2.2.3 Other lipid-based nanocarrier -- 4 Treatment of metastatic lung cancer -- 5 The mechanism of drug resistance in lung cancer and its associated treatments -- 6 Conclusions -- Acknowledgments -- References -- Chapter 9 Advanced drug delivery systems in lung cancer -- 1 Introduction -- 2 Nanoparticle drug delivery -- 2.1 Polymer-based nanoparticles -- 2.2 Inhalable nanoparticles -- 2.3 Lipid polymer hybrid nanoparticles -- 2.4 Hollow nanoparticles and nanoaggregates -- 3 Peptide-based nanoparticles -- 3.1 Quantum dots -- 4 Micelles -- 5 Dendrimers -- 6 Conclusion -- References -- Chapter 10 Advanced drug delivery systems in breast cancer -- 1 Introduction to breast cancer -- 2 Types of breast cancer -- 2.1 Breast cancer types based on histology -- 2.2 Molecular classification of breast cancer -- 3 Drugs approved/nonapproved for treating breast cancer -- 3.1 FDA-approved chemotherapeutic agent/hormonal/targeted drugs -- 3.2 Monoclonal antibodies -- 3.3 Other chemotherapeutic agent/phytocomponent/extracts -- 3.4 Nanoparticle itself showing anticancer activity against breast cancer -- 3.5 Genes therapy product -- 4 Conventional delivery systems -- 5 Advanced drug delivery system in breast cancer -- 6 Introduction of nanotechnology to breast cancer therapeutics -- 7 Nano-based advanced DDS in breast cancer -- 7.1 Vesicular drug delivery system -- 7.1.1 Liposomes -- 7.1.2 Niosomes -- 7.1.3 Phytosomes -- 7.1.4 Exosomes -- 7.1.5 Polymersomes -- 7.2 Nanoparticulate systems -- 7.2.1 Polymeric -- 7.2.2 Protein nanoparticles -- 7.2.3 Solid lipid nanoparticles and nanostructured lipid carriers -- 7.3 Micellar drug delivery system -- 7.4 Dendrimers -- 7.5 Nanoemulsions -- 7.6 Nanofibers -- 7.7 Layer-by-layer nanoparticles -- 7.8 Magnetic systems for drug delivery. , 7.9 Hybrid nanoparticles -- 7.10 Miscellaneous -- 8 Other advanced DDS -- 8.1 Transdermal patches in breast cancer -- 8.2 Microneedles -- 8.3 Other transdermal approaches -- 8.4 Implants -- 8.5 Injectable hydrogels -- 8.6 Microcapsules and microspheres -- 9 Antibody-drug conjugates -- 10 Physiological stimuli responsive-based ADD approach -- 11 Delivering micro/nanoparticles (drug-loaded or blank) -- 11.1 Delivering in the form of conventional DDS -- 11.2 Delivering as advanced transdermal approach -- 11.3 Surface modification of nanoparticles -- 11.3.1 To solve issues of nanoparticles -- 11.3.2 Surface modification to facilitate active targeting -- 11.4 Via external stimuli (ultrasound, magnetic field) -- 12 Conclusion -- References -- Chapter 11 Advanced drug delivery systems in the treatment of ovarian cancer -- 1 Introduction -- 2 Pathophysiology of ovarian cancer -- 3 Nanotools for the treatment of ovarian cancer -- 3.1 Passive targeting -- 3.2 Active targeting -- 3.2.1 Liposomes -- 3.2.2 Nanoemulsion -- 3.2.3 Micelle -- 3.2.4 Metal nanoparticles -- 3.2.5 Polymeric nanoparticles -- 3.2.6 Combination nanodrug therapy -- 4 Conclusion -- References -- Chapter 12 Advanced drug delivery systems in blood cancer -- 1 Introduction -- 2 Types of blood cancer -- 2.1 Leukemia -- 2.2 Lymphoma -- 2.3 Myeloma -- 3 Symptoms of blood cancer -- 4 Causes of blood Cancer -- 5 Pathophysiology in blood cancer -- 6 Blood cancer treatment -- 6.1 Chemotherapy -- 6.2 Radiation therapy -- 6.3 Immunotherapy -- 6.4 Gene therapy -- 7 Challenges in the blood cancer management -- 7.1 Biological barriers -- 7.2 Reticuloendothelial system -- 7.3 Renal system -- 7.4 Management -- 8 Blood cancer diagnosis -- 9 Current theranostic approach -- 10 Benefits and features of advanced drug delivery system. , 11 Advance drug delivery tool in the blood cancer management.

Language: English

UID:

Format: 1 online resource (620 pages)

ISBN: 0-12-820888-0

Additional Edition: ISBN 0-12-820658-6

Language: English

UID:

Format: 250 illus., 150 illus. in color. eReference.

Edition: 1st ed. 2024

ISBN: 9789819955756 , 9819955750

Additional Edition: Erscheint auch als Druck-Ausgabe Synbiotics in Human Health: Biology to Drug Delivery Singapore : Springer Nature Singapore, 2024 9789819955749

Additional Edition: 9789819955749

Language: English

DOI: 10.1007/978-981-99-5575-6

URL: https://doi.org/10.1007/978-981-99-5575-6

URL: Inhaltsverzeichnis

URL: Ausführliche Beschreibung

UID:

Format: 1 Online-Ressource (581 illus., 427 illus. in color. eReference)

Edition: 1st ed. 2024

ISBN: 9789819955756

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-9955-74-9

Language: English

DOI: 10.1007/978-981-99-5575-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (620 pages)

ISBN: 0-12-820888-0

Additional Edition: ISBN 0-12-820658-6

Language: English

UID:

Format: 1 online resource (574 pages)

ISBN: 0-323-90079-8 , 0-323-85503-2

Note: Intro -- Advanced Drug Delivery Systems in the Managementof Cancer -- Copyright -- Dedication -- Contents -- Contributors -- Editor biographies -- Chapter 1 Introduction to cancer cell biology -- 1 Introduction -- 2 Types of cancer -- 3 Pathophysiology of cancer -- 3.1 Sustained multiplication (proliferative) signaling -- 3.2 Shunning of anti-growth signals -- 3.3 Avoidance of immune annihilation (destruction) -- 3.4 Avoidance of apoptosis -- 3.5 Tissue invasion and metastasis -- 3.6 Extended (sustained) tumor angiogenesis -- 3.7 Endless multiplication (replication) potential -- 3.8 Deregulation of cell energetics -- 3.9 Oncogenes and tumor suppressor genes -- 3.10 Breast cancer biology -- 3.11 Gastric cancer biology -- 3.12 Pancreatic cancer biology -- 3.13 Lung cancer biology -- 3.14 Leukemia biology -- References -- Chapter 2 Current practice in cancer pharmacotherapy -- 1 Introduction -- 1.1 Lung -- 1.2 Breast (female) -- 1.3 Prostate -- 1.4 Colon -- 1.5 Skin -- 2 Conclusions -- References -- Chapter 3 Current practices in oncology drug delivery -- 1 Introduction -- 1.1 Historical background -- 1.2 Ancient theories about cancer -- 1.3 Description and epidemiology of cancer -- 2 Past therapeutic approaches in cancer (1900 and earlier) -- 3 Current approaches of drug delivery -- 3.1 Targeted therapy in cancer -- 3.1.1 Molecular targeted therapy -- 3.1.2 Monoclonal antibodies -- 3.1.3 Immunotoxins -- 3.2 Gene therapy -- 3.2.1 Gene therapy in clinics -- 3.3 Bacterial-mediated therapy -- 3.4 Nanomedicine -- 3.5 Immune checkpoint inhibitors -- 3.6 Radiomics and pathomics -- 3.6.1 Combining radiomics and pathomics with genomics -- 3.6.2 Combining radiomics and pathomics with artificial intelligence -- 3.6.3 Combining radiomics and pathomics with tumor markers. , 3.6.4 Combining radiomics with pathomics immunological detection -- 3.7 Theranostics -- 4 Future directions -- References -- Chapter 4 Emerging need of advanced drug delivery systems in cancer -- 1 Introduction -- 2 Multidrug resistance in cancer cells -- 3 Toxic effects of chemotherapy -- 4 Hazardous effects of radiation oncology -- 5 Polypharmacology in anticancer therapy -- 6 Advanced drug delivery systems -- 7 Stimuli-responsive drug delivery systems -- 7.1 pH-responsive -- 7.2 Light-responsive -- 7.3 Redox-responsive -- 7.4 Enzyme-responsive -- 8 Conclusion and future perspectives -- References -- Chapter 5 Target drug delivery in cancer -- 1 Introduction -- 2 Ligand-mediated targeting (surface modification) -- 2.1 Peptide as targeting ligand -- 2.2 Aptamer-mediated drug targeting -- 2.3 Small molecule-mediated targeted drug delivery -- 2.3.1 Folate receptor targeting -- 2.3.2 Anisamide-mediated targeting -- 2.3.3 Sugar-mediated targeting -- 3 Protein-mediated targeting -- 3.1 Antibody-mediated targeting -- 3.2 Transferrin-mediated targeting -- 3.3 Lectin-mediated drug delivery -- 4 Carbohydrate-mediated drug delivery -- 4.1 Hyaluronic-mediated targeted drug delivery -- 5 Physical targeting via EPR effects -- 6 Triggered targeting -- 7 Concluding remarks -- References -- Chapter 6 Material and strategies used in oncology drug delivery -- 1 Introduction -- 2 Materials and stratagem applied in cancer therapy -- 2.1 Nanocarriers for drug delivery -- 2.1.1 Inorganic nanocarriers -- 2.1.2 Organic nanocarriers -- 2.2 Protein-based nanocarriers -- 2.3 Micelles as a drug carrier -- 2.4 Self-assembly as a drug carrier -- 2.5 Supramolecules as a delivery vehicle -- 2.6 Hydrogel as a delivery vehicle -- 2.7 Hybrid materials for controlled drug delivery -- 3 Targeted delivery: Mechanistic pathway. , 3.1 Magnetic field for cancer treatment -- 3.2 Electric field for cancer therapy -- 3.3 Thermal treatment for cancer therapy -- 4 Future challenges in cancer therapy -- 5 Conclusions -- References -- Chapter 7 Hydrogel-based drug delivery systems for cancer therapy -- 1 Introduction -- 2 Hydrogels: An overview -- 3 Hydrogel-based drug delivery systems for cancer therapy -- 3.1 Hydrogels for oral delivery -- 3.1.1 Active targeting hydrogels -- 3.2 Injectable hydrogels for local cancer therapy -- 3.2.1 Local stimuli-sensitive hydrogels -- 3.2.2 External stimuli-responsive hydrogels -- 4 Marketed/patented hydrogel-based drug delivery systems -- 5 Conclusions and future perspectives -- References -- Chapter 8 Recent advances in drug formulation development for targeting lung cancer -- 1 Introduction -- 1.1 Mechanisms of metastasis and drug resistance in lung cancer -- 2 Immunotherapy: Biomolecules targeting lung cancer -- 2.1 Antibody-based biotherapies for lung cancer -- 2.1.1 Approved biomolecules targeting epidermal growth factor receptor (EGFR) -- 2.1.2 Approved biological molecules targeting vascular endothelial growth factor (VEGF) -- 2.1.3 Approved biological molecules targeting programmed cell death ligand (PD-1) -- 2.1.4 Biomolecules under development as promising candidates for treating lung cancer -- 3 Lung cancer therapy via inhalation -- 3.1 Clinical trials of inhaled chemotherapeutics: Success or failure? -- 3.1.1 Conventional chemotherapeutic drugs for therapeutic purposes -- 3.1.2 Nonchemotherapeutic drugs as cancer chemoprevention agent -- 3.2 Current technological advances in inhalable drug delivery system (DDS) -- 3.2.1 Representative inhalable DDS based on the drug encapsulation into microparticles -- 3.2.2 Inhalable DDS based on nanotechnology approach -- 3.2.2.1 Liposome. , 3.2.2.2 Polymeric nanoparticle -- 3.2.2.3 Other lipid-based nanocarrier -- 4 Treatment of metastatic lung cancer -- 5 The mechanism of drug resistance in lung cancer and its associated treatments -- 6 Conclusions -- Acknowledgments -- References -- Chapter 9 Advanced drug delivery systems in lung cancer -- 1 Introduction -- 2 Nanoparticle drug delivery -- 2.1 Polymer-based nanoparticles -- 2.2 Inhalable nanoparticles -- 2.3 Lipid polymer hybrid nanoparticles -- 2.4 Hollow nanoparticles and nanoaggregates -- 3 Peptide-based nanoparticles -- 3.1 Quantum dots -- 4 Micelles -- 5 Dendrimers -- 6 Conclusion -- References -- Chapter 10 Advanced drug delivery systems in breast cancer -- 1 Introduction to breast cancer -- 2 Types of breast cancer -- 2.1 Breast cancer types based on histology -- 2.2 Molecular classification of breast cancer -- 3 Drugs approved/nonapproved for treating breast cancer -- 3.1 FDA-approved chemotherapeutic agent/hormonal/targeted drugs -- 3.2 Monoclonal antibodies -- 3.3 Other chemotherapeutic agent/phytocomponent/extracts -- 3.4 Nanoparticle itself showing anticancer activity against breast cancer -- 3.5 Genes therapy product -- 4 Conventional delivery systems -- 5 Advanced drug delivery system in breast cancer -- 6 Introduction of nanotechnology to breast cancer therapeutics -- 7 Nano-based advanced DDS in breast cancer -- 7.1 Vesicular drug delivery system -- 7.1.1 Liposomes -- 7.1.2 Niosomes -- 7.1.3 Phytosomes -- 7.1.4 Exosomes -- 7.1.5 Polymersomes -- 7.2 Nanoparticulate systems -- 7.2.1 Polymeric -- 7.2.2 Protein nanoparticles -- 7.2.3 Solid lipid nanoparticles and nanostructured lipid carriers -- 7.3 Micellar drug delivery system -- 7.4 Dendrimers -- 7.5 Nanoemulsions -- 7.6 Nanofibers -- 7.7 Layer-by-layer nanoparticles -- 7.8 Magnetic systems for drug delivery. , 7.9 Hybrid nanoparticles -- 7.10 Miscellaneous -- 8 Other advanced DDS -- 8.1 Transdermal patches in breast cancer -- 8.2 Microneedles -- 8.3 Other transdermal approaches -- 8.4 Implants -- 8.5 Injectable hydrogels -- 8.6 Microcapsules and microspheres -- 9 Antibody-drug conjugates -- 10 Physiological stimuli responsive-based ADD approach -- 11 Delivering micro/nanoparticles (drug-loaded or blank) -- 11.1 Delivering in the form of conventional DDS -- 11.2 Delivering as advanced transdermal approach -- 11.3 Surface modification of nanoparticles -- 11.3.1 To solve issues of nanoparticles -- 11.3.2 Surface modification to facilitate active targeting -- 11.4 Via external stimuli (ultrasound, magnetic field) -- 12 Conclusion -- References -- Chapter 11 Advanced drug delivery systems in the treatment of ovarian cancer -- 1 Introduction -- 2 Pathophysiology of ovarian cancer -- 3 Nanotools for the treatment of ovarian cancer -- 3.1 Passive targeting -- 3.2 Active targeting -- 3.2.1 Liposomes -- 3.2.2 Nanoemulsion -- 3.2.3 Micelle -- 3.2.4 Metal nanoparticles -- 3.2.5 Polymeric nanoparticles -- 3.2.6 Combination nanodrug therapy -- 4 Conclusion -- References -- Chapter 12 Advanced drug delivery systems in blood cancer -- 1 Introduction -- 2 Types of blood cancer -- 2.1 Leukemia -- 2.2 Lymphoma -- 2.3 Myeloma -- 3 Symptoms of blood cancer -- 4 Causes of blood Cancer -- 5 Pathophysiology in blood cancer -- 6 Blood cancer treatment -- 6.1 Chemotherapy -- 6.2 Radiation therapy -- 6.3 Immunotherapy -- 6.4 Gene therapy -- 7 Challenges in the blood cancer management -- 7.1 Biological barriers -- 7.2 Reticuloendothelial system -- 7.3 Renal system -- 7.4 Management -- 8 Blood cancer diagnosis -- 9 Current theranostic approach -- 10 Benefits and features of advanced drug delivery system. , 11 Advance drug delivery tool in the blood cancer management.

Language: English

UID:

Format: 1 Online-Ressource (581 illus., 427 illus. in color. eReference).

Edition: 1st ed. 2024

ISBN: 978-981-9955-75-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-9955-74-9

Language: English

DOI: 10.1007/978-981-99-5575-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource(581 illus., 427 illus. in color. eReference.)

Edition: 1st ed. 2024.

ISBN: 9789819955756

Content: Introduction to Synbiotics -- Role of Synbiotics on modulation of inflammation -- Role of synbiotics in inflammatory lung diseases -- Role of Synbiotics in Neurodegenerative Diseases -- Role of Synbiotics in Gastrointestinal Disorders -- Role of Synbiotics in Cardiovascular diseases -- ROLE OF SYNBIOTICS IN THROMBOTIC DISORDERS -- Role of Synbiotics in Reproductive disorders -- Role of Synbiotics in Metabolic Disorders -- SYNBIOTICS FOR THE PREVENTION AND TREATMENT OF SKIN DISORDERS -- Cellular and Molecular mechanisms involving synbiotics in various disease state -- Clinical Trial with Synbiotics in Various Disease State -- FUTURE PERSPECTIVE AND SAFETY ISSUES OF SYNBIOTICS IN DIFFERENT DISEASES -- Role of nutraceutical-based synbiotics in the biological homeostasis -- Synergistic welfare of synbiotic nutraceuticals on chronic respiratory diseases -- Synergistic welfare of symbiotic nutraceuticals on gut health -- Synergistic welfare of synbiotic nutraceuticals on neurological function -- SynergisticWelfare of Synbiotic Nutraceuticals on Reproductive Health -- Quality Control and Evaluation of Synbiotics Neutraceutical Product -- Toxicological profile of nutraceutical supplements -- TRANSLATIONAL RESEARCH & CLINICAL ADVANCEMENTS WITH NUTRACEUTICAL SUPPLEMENTS -- Regulatory Aspects and Bottlenecks for Nutraceuticals -- Future prospects and advancement in synbiotics containing Nutraceuticals -- Synbiotics and Drug Delivery: An introduction -- Emerging era of “biotics”: Prebiotics, probiotics and synbiotics -- Therapeutic potential of synbiotics in management of various disorders -- Synbiotics: Safety assessment and role in the prevention of diseases -- Synbiotics as a nutraceutical adjuvant: neuroprotective and neurorestorative effects -- Synbiotics: Complementary and synergistic approach against different carcinomas -- SYNBIOTICS IN ORAL DRUG DELIVERY -- Applications of synbiotics as cosmeceuticals -- Advanced drug delivery approaches containing synbiotics -- Ideal Synbiotics: Pharmacokinetic, pharmacodynamic and safety assessment -- Regulatory Aspects of Synbiotics-Based Delivery System -- An update on clinical trials on synbiotics.

Content: This reference book discusses the role of synbiotics in a wide range of disease states, including cardiovascular, reproductive, metabolic, neurodegenerative, gastrointestinal, thrombotic, skin, and inflammatory disorders. It reviews the functions of probiotics in the diagnosis, prevention, or treatment of various disease states. The book further covers improving the targeting efficiency of synbiotics through advanced drug delivery systems such as nanoparticles, microparticles, liposomes, microemulsion, solid lipid nanoparticles, and nano lipid carriers. The chapter addresses the implications of oral and topical delivery of synbiotics in different diseases and presents the safety assessment of synbiotics and clinical trials associated with synbiotics containing drug delivery systems for the treatment of diseases. The book also explores the synergistic welfare of synbiotics nutraceuticals in various conditions such as chronic respiratory diseases, gut health, and neurological functions and examines the toxicological profile, and regulatory aspects of nutraceutical supplements. As such, this book is a valuable resource for academics, research and industry professionals working in Pharmaceutical Sciences, Food Biotechnology, Immunology, and Health Sciences.

Additional Edition: 9789819955749

Additional Edition: Erscheint auch als Druck-Ausgabe 9789819955749

Language: English

DOI: 10.1007/978-981-99-5575-6

URL: lizenzpflichtig

UID:

Format: 1 Online-Ressource (581 illus., 427 illus. in color. eReference)

Edition: 1st ed. 2024

ISBN: 9789819955756

Additional Edition: Printed edition 9789819955749

Language: English

DOI: 10.1007/978-981-99-5575-6

URL: https://doi.org/10.1007/978-981-99-5575-6